Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Ghost
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon May 15, 2023 11:02am
88 Views
Post# 35448238

RE:RE:RE:RE:RE:RE:RE:Ghost

RE:RE:RE:RE:RE:RE:RE:GhostHey, TT, tell us what you think of the Biodexa/Midatech's 13G filings.

Why do you suppose these people bellied up to such a failure as Midatech? What do they have in mind?

Why have they gone through so much to get control of Biodexa? What might their plans be? Follow the money, TT.

What are Ladenburg Thalmann's parts in all this? Who do they represent? Everybody? Really? Whose interests are foremost in their plans?

Why is Bioasis taking itself to the financial cliff? Do they want to be able to say they have no choice but to sell Bioasis (and xB3) for a penny?

About reading the documents, TheTruth1234, have you ever read any or do you only read Stockhouse?

You can tell us The Truth. It's as easy as 1234.

Well, for some people it is.

Love,

Your friend,

John Boy

You're right, you can't make up this stuff. Truly, you are dying here.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities